Evidence map›Paper›PMID 35851833›Full record

ArticleScientific reports2022

Sirtuin 5 levels are limiting in preserving cardiac function and suppressing fibrosis in response to pressure overload.

Angela H Guo, Rachael Baliira, Mary E Skinner, Surinder Kumar, Anthony Andren, Li Zhang, Robert S Goldsmith, Shaday Michan, Norma J Davis, Merissa W Maccani and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Emerging interactions between mitochondria and NADTrends in endocrinology and metabolism: TEM · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Angela H GuoDepartment of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
Rachael BaliiraDepartment of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
Mary E SkinnerDepartment of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
Surinder KumarDepartment of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
Anthony AndrenDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, 48109, USA.
Li ZhangDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, 48109, USA.
Robert S GoldsmithDepartment of Pharmacology, University of Michigan, Ann Arbor, MI, 48109, USA.
Shaday MichanDepartment of Genetics, Harvard Medical School, Boston, MA, 02115, USA.
Norma J DavisDepartment of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
Merissa W MaccaniDepartment of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
Sharlene M DayDivision of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, USA.
David A SinclairDepartment of Genetics, Harvard Medical School, Boston, MA, 02115, USA.
Matthew J BrodyDepartment of Pharmacology, University of Michigan, Ann Arbor, MI, 48109, USA.
Costas A LyssiotisDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, 48109, USA.
Adam B SteinDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
David B LombardDepartment of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA. dbl68@miami.edu.
University of Michigan–Ann Arbor · USGalena Biopharma (United States) · USHarvard University · USUniversity of Pennsylvania · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Research Training in BiogerontologyT32AG000114 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCOTT PLETCHER · 1985 to 2026
$12.4M
Statistics and Bioinformatics Core - WangU24DK097153 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BURANT, CHARLES F · 2012 to 2017
$10.1M
University of Michigan Postbaccalaureate Research Education Program (UM PREP)R25GM086262 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALLEN, BENJAMIN · 2009 to 2024
$6.1M
SIRT1 as a regulator of health and lifespan of mammalsR37AG028730 · NIA · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2012 to 2021
$4.1M
Regulation of one carbon metabolism and epigenetics by SIRT5R01GM101171 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOMBARD, DAVID BENNER · 2012 to 2021
$2.6M
Stromal metabolism promotes therapeutic resistance in pancreatic cancerR01CA248160 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LYSSIOTIS, COSTAS ANDREAS · 2020 to 2024
$2.0M
Targeting metabolic stress to induce pancreatic tumor cell deathR01CA244931 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LYSSIOTIS, COSTAS ANDREAS · 2020 to 2024
$1.9M
Training Program in Translational ResearchT32GM113900 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIEBERMAN, ANDREW P, NIKOLOVSKA-COLESKA, ZANETA · 2016 to 2020
$991k
The role of palmitoylation in cardiac signal transduction and disease pathogenesisR00HL136695 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BRODY, MATTHEW JACOB · 2019 to 2021
$747k
Elucidating epigenetic mechanisms of cellular cadmium toxicityR21ES032305 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOMBARD, DAVID BENNER · 2020 to 2021
$427k
NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA244931NCI NIH HHS R01 CA248160NCI NIH HHS R01CA248160NHLBI NIH HHS R00 HL136695NHLBI NIH HHS R00HL136695NIA NIH HHS R37 AG028730NIA NIH HHS R37AG028730NIA NIH HHS T32 AG000114NIA NIH HHS T32AG000114NIDDK NIH HHS U24 DK097153NIEHS NIH HHS R21 ES032305NIEHS NIH HHS R21ES032305NIGMS NIH HHS R01 GM101171NIGMS NIH HHS R01GM101171NIGMS NIH HHS R25 GM086262NIGMS NIH HHS R25GM086262NIGMS NIH HHS T32 GM113900NIGMS NIH HHS T32GM113900
6 · The paper itself

Abstract

Heart failure (HF) is the inability of the heart to pump blood sufficiently to meet the metabolic demands of the body. HF with reduced systolic function is characterized by cardiac hypertrophy, ventricular fibrosis and remodeling, and decreased cardiac contractility, leading to cardiac functional impairment and death. Transverse aortic constriction (TAC) is a well-established model for inducing hypertrophy and HF in rodents. Mice globally deficient in sirtuin 5 (SIRT5), a NAD

Indexed as

Heart FailureSirtuinsAnimalsCardiomegalyDisease Models, AnimalFibrosisMiceMice, Inbred C57BLMyocardiumVentricular RemodelingSIRT5 protein, mouseSirtuins

Identifiers

PMID35851833
PMCPMC9293976
OpenAlexW4285727675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.